89Bio, Inc. Stock Price, News & Analysis

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 1:10 p.m. ET. The event will be virtual, and the presentation can be accessed via the Oppenheimer conference portal, with an archived version available on 89bio’s investor website. The company focuses on innovative therapies for liver and cardio-metabolic diseases, with its leading product candidate, BIO89-100, targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, a clinical-stage biopharmaceutical company, announced participation in the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. EST on March 9, with an archived webcast accessible on 89bio’s website. The company focuses on innovative therapies for liver and cardio-metabolic diseases, notably their lead candidate BIO89-100, targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is based in San Francisco.

89bio, a clinical-stage biopharmaceutical company, announced it will provide a corporate update and engage in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 12:30 PM ET. The presentation will be accessible via the conference portal. 89bio focuses on therapies for liver and cardio-metabolic diseases, with its lead product BIO89-100 targeting NASH and severe hypertriglyceridemia.

89bio, a clinical-stage biopharmaceutical company specializing in treatments for liver and cardio-metabolic diseases, announced a corporate update at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 5:00 PM ET. The event will feature one-on-one investor meetings and a presentation accessible via the conference portal. The company's lead candidate, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). For more details, the webcast will be archived on 89bio’s investor section.

89bio, Inc. (Nasdaq: ETNB) announced significant advancements in its clinical development program for BIO89-100, targeted at liver and cardio-metabolic diseases. The company is set to initiate a Phase 2b NASH trial in 1H21 and expects topline data from the open-label histology cohort by year-end 2021. The Phase 2 SHTG trial is also underway, with results anticipated in 2H21. Encouraging data from a previous Phase 1b/2a trial indicated reductions in liver fat of up to 70% and significant improvements in ALT and triglycerides, showcasing the positive risk-benefit profile of BIO89-100.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardio-metabolic diseases, will present a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Rohan Palekar's presentation will be available on-demand starting at 6 a.m. EST on January 11. The archived webcast can be accessed in the investor section of 89bio’s website. The company’s lead product, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, Inc (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, will have its CEO, Rohan Palekar, participate in investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020. The conference runs from December 1-3, 2020. An archived webcast of the discussion will be available on 89bio’s website.

89bio is focused on therapies for liver and cardio-metabolic diseases, with its lead candidate, BIO89-100, aimed at treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, Inc. (Nasdaq: ETNB) announced updated positive data from its Phase 1b/2a study of BIO89-100, a treatment for nonalcoholic steatohepatitis (NASH). The study demonstrates significant reductions in liver fat, ALT levels, and triglycerides across various dosing groups with favorable tolerability. Notably, 88% of patients achieved a ≥30% reduction in liver fat. The company plans to initiate a Phase 2b study in early 2021, emphasizing its commitment to addressing NASH's unmet medical needs.

89bio, Inc. (Nasdaq: ETNB) announced significant advancements in its clinical development program during Q3 2020. Positive results from the Phase 1b/2a trial of BIO89-100 for NASH highlighted a 70% liver fat reduction and excellent tolerability. The company is set to present data at the AASLD Liver Meeting and initiate a Phase 2b trial in NASH in H1 2021. Financially, 89bio reported a net loss of $14.6 million, improving from $18.7 million year-over-year, with cash reserves at $219.2 million, supporting ongoing research initiatives.